AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.

J. James
Abstract: The Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee is questioning whether results of four clinical trials should change the standard use of AZT (Retrovir), especially in combination with ddI and ddC. Results from the ACTG 175, the Delta trials, CPCRA 007, and ACTG 152 were reviewed. AZT plus either ddI or ddC was shown to be more effective than AZT alone. The Committee approved the use of ddI as an initial treatment for HIV disease, and approved AZT plus ddC for use in persons with no prior use of antiretrovirals. 3TC is believed to be more effective than either ddI or ddC, but clinical endpoint data is not yet available.
What problem does this paper attempt to address?